Fabry Outcome Survey (FOS)
NCT03289065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000
Last updated 2021-11-16
Summary
The purpose of this study is to collect data that will increase understanding of Fabry disease history and progression, in treated and untreated patients with Fabry disease. The data from FOS may provide guidance to healthcare professionals about disease treatment options.
Conditions
Sponsors & Collaborators
-
Shire
lead INDUSTRY
Principal Investigators
-
Study Director · Shire
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-04-01
- Primary Completion
- 2021-09-30
- Completion
- 2021-09-30
Countries
- United States
Study Locations
More Related Trials
-
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
NCT02800070 ·Status: COMPLETED ·Phase: PHASE1
-
Investigating Lysosomal Storage Diseases in Minority Groups
NCT02120235 ·Status: UNKNOWN
-
Evaluation of Phenotypic Variability in Fabry Disease
NCT03145779 ·Status: WITHDRAWN
-
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
NCT06065605 ·Status: UNKNOWN
-
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease
NCT05046379 ·Status: COMPLETED
-
Fabry and Cardiomyopathy (FaCard)
NCT01429597 ·Status: WITHDRAWN
-
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
NCT02194985 ·Status: COMPLETED ·Phase: PHASE3
-
An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression
NCT06079567 ·Status: RECRUITING ·Phase: NA
-
Hunter Outcome Survey (HOS)
NCT03292887 ·Status: COMPLETED
-
Characterisation of Heart Involvement in Fabry Disease With T1 Mapping
NCT04708301 ·Status: COMPLETED
-
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
NCT03230149 ·Status: COMPLETED
-
Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT05039866 ·Status: ENROLLING_BY_INVITATION
-
A Fabry Disease Gene Therapy Study
NCT04040049 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Ten Year Follow-up in FSHD: the FOCUS 3 Study
NCT06911190 ·Status: RECRUITING
-
Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease
NCT04916977 ·Status: COMPLETED
-
French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat
NCT04602364 ·Status: COMPLETED
-
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
NCT02921620 ·Status: WITHDRAWN ·Phase: PHASE3
-
Extension Study of PRX-102 for up to 60 Months
NCT01981720 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
T1 Mapping in Fabry Disease
NCT05923788 ·Status: RECRUITING ·Phase: NA
-
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
NCT03683966 ·Status: UNKNOWN
-
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
NCT03566017 ·Status: COMPLETED ·Phase: PHASE3
-
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742 ·Status: RECRUITING
-
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
NCT05710692 ·Status: RECRUITING ·Phase: PHASE2/PHASE3